Companion Diagnostics For Breakthrough Drugs Also Getting Swift Attention, FDA Says
Executive Summary
Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough therapies from coming to market.
You may also be interested in...
From “Safe Harbor” To Spotlight: Pharmacogenomics Comes Of Age At FDA
An FDA/industry workshop on pharmacogenomics and biomarkers highlighted how far the regulatory system for PKG has evolved. Where industry was afraid to share data with FDA, the conversation is now about how to get the agency the resources it needs to review the data effectively.
Drug/Diagnostic Co-Development Guidance Coming Soon, But Could Be Outdated Quickly
Tests that look for many markers at one time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.
Drug/Diagnostic Co-Development Guidance Coming Soon, But Could Be Outdated Quickly
Tests that look for many markers at one time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.